Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Abstract:
Only two years ago an American-Dutch research effort was the first trialling nanotherapy in cardiovascular patients. Since then they took some remarkable steps towards the use of a combination of endogenous nanoparticles and cannabinoids to treat atherosclerosis. Ground-breaking projects demand innovative ways to create publicity and gather funding. The non-profit organization High on Nano aims to crowd fund a documentary about this topic to support the research.

High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Amsterdam, Netherlands | Posted on December 4th, 2013

The development of nanotechnologies to encapsulate drugs in tiny nanoparticles has witnessed tremendous growth in the last two decades. These nanoparticles are designed for accurate delivery of imaging agents and/or drugs at diseased sites, increasing precision hits while hopefully lowering side effects. Unfortunately the large amount of promising research projects -mainly focusing on oncologic targets- only reported limited clinical successes so far.

For the exploration of nanotechnology in cardiovascular medicine the Dutch chemist Willem Mulder founded the Nanomedicine Laboratory at the Icahn School of Medicine at Mount Sinai in 2006. The nanoparticle platforms his team develops are designed to specifically target atherosclerotic plaques, the underlying cause of cardiovascular disease. In cooperation with the Academic Medical Center in Amsterdam the first-in-man trials with synthetic nanoparticles were initiated already in 2011. In preclinical studies the exploitation of endogenous nanoparticles has shown promise in the context of cardiovascular disease, as such nanoparticles exhibit a natural affinity for atherosclerotic plaques. These particles create an attractive and natural drug delivery platform for atherosclerotic targets.

One of the potent anti-atherosclerotic drug classes they investigate is cannabinoids. In 2005 a seminal study published in the journal Nature demonstrated that low dose oral cannabinoid therapy reduces the progression of atherosclerosis in mice. However, research activity in this area has been relatively subdued. This may be -in part- attributed to psychotropic side effects, and poor specificity and bioavailability of orally administered cannabinoids. To overcome these limitations, nanoparticle formulations may offer an attractive alternative.

Atherosclerosis is also known as ‘hardening' of the arteries. It is a result of genetics, high cholesterol, high blood pressure and smoking cigarettes. It is a common underlying cause of cardiovascular diseases, including heart attack and stroke, and represents the highest expenditure of the world health care (app €198 billion in EU and $300 billion in the US).

Every year about 1,3 million people die from cardiovascular disease in the US and 1,6 million in Europe.

In patients who suffered a heart attack the recurrence risk of an acute coronary syndrome is high, particularly within the first three years when recurrence rates are up to over 20%.

The Dutch Non-profit organization High on Nano was founded on October 28th. Their goal is to popularise the work of Willem Mulder and his teams by developing a documentary (series) about his work.

####

About www.HighonNano.com
To support this project, non-profit organization High on Nano was recently founded. Their aim is to familiarize the general public with this exciting field and establish innovative mechanisms to help fund the research. The first step is crowd funding a documentary to show the world what is going on in the field of 21st century nanomedicine. They hope this process, and the resulting publicity, ultimately open up ways to fund part of the research.

For more information, please click here

Contacts:
Gert van Kempen
Chairman
Non-profit Organization High on Nano

http://www.facebook.com/HighonNano

Copyright © www.HighonNano.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Article:

Clinical trials:

Clinical trials:

Article:

Abstract:

Related News Press

News and information

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Generating power where seawater and river water meet July 22nd, 2022

First electric nanomotor made from DNA material: Synthetic rotary motors at the nanoscale perform mechanical work July 22nd, 2022

At the water’s edge: Self-assembling 2D materials at a liquid–liquid interface: Scientists find a simple way to produce heterolayer coordination nanosheets, expanding the diversity of 2D materials July 22nd, 2022

Videos/Movies

Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022

Visualizing the invisible: New fluorescent DNA label reveals nanoscopic cancer features March 4th, 2022

OCSiAl receives the green light for Luxembourg graphene nanotube facility project to power the next generation of electric vehicles in Europe March 4th, 2022

Nanotube fibers stand strong -- but for how long? Rice scientists calculate how carbon nanotubes and their fibers experience fatigue December 24th, 2021

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Nanomedicine

How different cancer cells respond to drug-delivering nanoparticles: The findings of a large-scale screen could help researchers design nanoparticles that target specific types of cancer July 22nd, 2022

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Study reveals new mode of triggering immune responses July 15th, 2022

UNC Charlotte-led team invents new anticoagulant platform, offering hope for advances for heart surgery, dialysis, other procedures July 15th, 2022

Announcements

Quantum computer works with more than zero and one: Quantum digits unlock more computational power with fewer quantum particles July 22nd, 2022

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Generating power where seawater and river water meet July 22nd, 2022

First electric nanomotor made from DNA material: Synthetic rotary motors at the nanoscale perform mechanical work July 22nd, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project